Silanized acrylic graphene oxide nanocomposite reinforced mechanically tunable GelMA/HAMA printable bio-ink for adipose-derived stem cells differentiated mature smooth muscle cells.
Atturu P., Lee SS., Chang PC., Chiou K., Wang CK.
Animal Study, published in Biomater Adv (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biomater Adv (2025)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 39983498
- DOI
- 10.1016/j.bioadv.2025.214226
- Citations
- 3
Abstract (original English)
Smooth muscle cells (SMCs) phenotype has successfully conserved in the 3D printable GH-ASG bio-inks composed of silanized acrylic graphene oxide nanosheets as a crosslinker (APStriol@GO) comprising of 3-acryloyloxypropyl silanetriol (APStriol) and graphene oxide (GO) reinforced in the hybrid hydrogel consist of methacrylated gelatin (GelMA) and methacrylated hyaluronic acid (HAMA) to develop a photocurable hybrid novel bio-ink (GelMA/HAMA/APStriol@GO) as a component for rabbit adipose-derived stem cells (rADSCs) differentiated SMCs inducing functionalized material in situ. Hybrid GH-ASG hydrogels were evaluated for various physiochemical parameters and chemical modifications. The GH-ASG4 (GelMA/HAMA/APStriol@GO-1 %) bioink exhibited optimal reactive oxygen species scavenging potential, and hemostasis was shown to enhance the viability of rADSCs. Additionally, the morphology and nucleus count for differentiated SMCs were analyzed employing TRAP staining. Moreover, the contractile SMCs phenotype was determined at the transcript level by implementing quantitative RT-PCR using SMCs-specific gene markers (α-SMA and SM-MHC). The protein level of gene expression was assessed through Immunocytochemistry and western blot analysis using SMC-specific antibodies (α-SMA and SM-MHC). GH-ASG4 bio-ink was used for 3D printed tubular and disk scaffold fabrication through extrusion bioprinting w
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.